Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.

ABSTRACT: During the last several years, multiple gene rearrangements with oncogenic potential have been described in NSCLC, identifying specific clinic-pathological subgroups of patients that benefit from a targeted therapeutic approach, including anaplastic lymphoma kinase (ALK), c-ros protooncogene 1 (ROS1) and, more recently, REarranged during Transfection (RET) and neurotrophic tyrosine receptor kinases (NTRK) genes. Despite initial impressive antitumor activity, the use of targeted therapies in oncogene-addicted NSCLC subgroups is invariably associated with the development of acquired resistance through multiple mechanisms that can include both on-target and off-target mechanisms. However, the process of acquired resistance is a rapidly e

SUBMITTER: Russo A 

PROVIDER: S-EPMC7815353 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature